A privately held specialty biopharmaceutical start-up focused on creating products for use in the largest and fastest growing sectors of the dermatology market.
Company founded with the mission to develop the first effective topically-applied treatment for the erythema (skin redness) associated with rosacea.
Innovator in the development of ()-adrenergic receptor technology pursuing indications which include the treatment and prevention of Rosacea, Actinic (Solar) Purpura and peri-procedural bruising of the skin.